Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017
Use of bosentan for the treatment of pulmonary arterial hypertension in Spain: a multicenter, retrospective, observational study Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009
Prevalence of chronic thrombo-embolic pulmonary hypertension after pulmonary embolism: A prospective multicenter study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010
Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018
Pulmonary embolism in the multicentre advanced study for a thromboembolism registry (MASTER): study design and patients recruited Source: Eur Respir J 2005; 26: Suppl. 49, 595s Year: 2005
Initial results of the UK audit of chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2007; 30: Suppl. 51, 486s Year: 2007
Multi-institutional prospective registry in pulmonary hypertension associated with respiratory disease in Japan. Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018
Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry Source: ERJ Open Res, 7 (3) 00850-2020; 10.1183/23120541.00850-2020 Year: 2021
The incidence of chronic thromboembolic pulmonary hypertension (CTEPH): a 25-year population-based study Source: Eur Respir J 2003; 22: Suppl. 45, 462s Year: 2003
Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension (CTEPH) as early follow-up treatment after pulmonary endarterectomy (PEA) – a prospective cohort study Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020
First international registry on chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008
Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism Source: Eur Respir J, 51 (4) 1702505; 10.1183/13993003.02505-2017 Year: 2018
Management of chronic thromboembolic pulmonary hypertension (CTEPH): A physician-based perception study Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012
Adherence to guidelines of anticoagulant prescription in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an observational study Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020
A multicentre observational study of the prevalence, management and outcomes of subsegmental pulmonary embolism Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism Year: 2020
Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study Source: ERJ Open Res, 7 (3) 00082-2021; 10.1183/23120541.00082-2021 Year: 2021
Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015
Results of European post-marketing surveillance of bosentan in pulmonary hypertension Source: Eur Respir J 2007; 30: 338-344 Year: 2007